WO2002033079A3 - Human g-protein coupled receptor and uses thereof - Google Patents

Human g-protein coupled receptor and uses thereof Download PDF

Info

Publication number
WO2002033079A3
WO2002033079A3 PCT/EP2001/011371 EP0111371W WO0233079A3 WO 2002033079 A3 WO2002033079 A3 WO 2002033079A3 EP 0111371 W EP0111371 W EP 0111371W WO 0233079 A3 WO0233079 A3 WO 0233079A3
Authority
WO
WIPO (PCT)
Prior art keywords
igs58
polynucleotides
receptor family
protein coupled
coupled receptor
Prior art date
Application number
PCT/EP2001/011371
Other languages
French (fr)
Other versions
WO2002033079A2 (en
Inventor
Willy Deleersnijder
Herman Blockx
Moor Lucie De
Original Assignee
Solvay Pharm Bv
Willy Deleersnijder
Herman Blockx
Moor Lucie De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Willy Deleersnijder, Herman Blockx, Moor Lucie De filed Critical Solvay Pharm Bv
Priority to EP20010980469 priority Critical patent/EP1334191A2/en
Priority to AU2002212304A priority patent/AU2002212304A1/en
Priority to JP2002536447A priority patent/JP2004514426A/en
Publication of WO2002033079A2 publication Critical patent/WO2002033079A2/en
Publication of WO2002033079A3 publication Critical patent/WO2002033079A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the IGS58 G-protein coupled receptor family, and to polynucleotides encoding said IGS58 proteins. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and non-human transgenic animals where the IGS58-gene is either overexpressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS58 and the use of IGS58 polypeptides and polynucleotides and agonists or antagonists to the IGS58 receptor family in the treatment of a broad range of disorders and diagnostic assays for such conditions. The invention in particular relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS58 and the use of IGS58 polypeptides and polynucleotides and agonists or antagonists to the IGS58 receptor family in the treatment of dysfunctions, disorders, or diseases related to testis, prostate, uterus, heart, kidney, lung, trachea, skeletal muscle, adrenal gland, thyroid, and the central nervous system, such as fetal brain, brain, cerebellum, spinal cord, caudate nucleus, amygdala, corpus callosum, hippocampus, and thalamus, and diagnostic assays for such conditions.
PCT/EP2001/011371 2000-10-16 2001-10-01 Human g-protein coupled receptor and uses thereof WO2002033079A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20010980469 EP1334191A2 (en) 2000-10-16 2001-10-01 Human g-protein coupled receptor and uses thereof
AU2002212304A AU2002212304A1 (en) 2000-10-16 2001-10-01 Human g-protein coupled receptor and uses thereof
JP2002536447A JP2004514426A (en) 2000-10-16 2001-10-01 Human G protein-coupled receptor and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00203566.5 2000-10-16
EP00203566 2000-10-16
US24137200P 2000-10-19 2000-10-19
US60/241,372 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002033079A2 WO2002033079A2 (en) 2002-04-25
WO2002033079A3 true WO2002033079A3 (en) 2002-09-19

Family

ID=56290198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011371 WO2002033079A2 (en) 2000-10-16 2001-10-01 Human g-protein coupled receptor and uses thereof

Country Status (4)

Country Link
EP (1) EP1334191A2 (en)
JP (1) JP2004514426A (en)
AU (1) AU2002212304A1 (en)
WO (1) WO2002033079A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2374596A (en) * 2000-12-12 2002-10-23 Glaxo Group Ltd An isolated histamine like receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098351A2 (en) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. G-protein coupled receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098351A2 (en) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. G-protein coupled receptors

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIKKER J.A. ET AL.: "G-protein coupled receptors: models, mutagenesis, and drug design", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 16, 30 July 1998 (1998-07-30), pages 2911 - 2927, XP000876776, ISSN: 0022-2623 *
DATABASE EMBL [online] 2 September 1999 (1999-09-02), "Homo sapiens leukocyte platelet-activating factor receptor mRNA, complete cds.", XP002168124, Database accession no. M76676 *
DATABASE EMBL [online] 25 May 2000 (2000-05-25), XP002168123, Database accession no. AL162471 *
DATABASE EMBL [online] 6 March 2000 (2000-03-06), XP002168122, Database accession no. AL159140 *
EDVARDSEN O. AND KRISTIANSEN K.: "Internet resources on G-protein-coupled receptors", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 6, 1 June 1997 (1997-06-01), pages 226 - 227, XP004074685, ISSN: 0968-0004 *
FLOWER D.R.: "Modelling G-protein-coupled receptors for drug design", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1422, no. 3, 16 November 1999 (1999-11-16), pages 207 - 234, XP004281748, ISSN: 0304-4157 *
HALAZY S.: "G-protein coupled receptors bivalen ligands and drug design", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 9, no. 4, 1999, pages 431 - 446, XP000882817, ISSN: 1354-3776 *
LEE N.H. KERLAVAGE A.R.: "Molecular biology of G-protein-coupled receptors", DRUG NEWS AND PERSPECTIVES, vol. 6, no. 7, 1 September 1993 (1993-09-01), pages 488 - 497, XP000677175, ISSN: 0214-0934 *
RHEE VAN A.M. AND JACOBSON K.A.: "Molecular architecture of G protein-coupled receptors", DRUG DEVELOPMENT RESEARCH, vol. 37, no. 1, January 1996 (1996-01-01), pages 1 - 38, XP001011411, ISSN: 0272-4391 *
STRADER C.D. ET AL.: "Structure and function of G protein-coupled receptors", ANNUAL REVIEW OF BIOCHEMISTRY, vol. 63, 1994, pages 101 - 132, XP001041816, ISSN: 0066-4154 *

Also Published As

Publication number Publication date
JP2004514426A (en) 2004-05-20
WO2002033079A2 (en) 2002-04-25
AU2002212304A1 (en) 2002-04-29
EP1334191A2 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
Tsutsumi et al. Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor.
Iwahara et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
Foguet et al. Cloning and functional characterization of the rat stomach fundus serotonin receptor.
Rees et al. Cloning and characterisation of the human 5‐HT5A serotonin receptor
Kieffer et al. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.
Rose et al. Cloning and Functional Expression of a cDNA Encoding a Human Type 2 Neuropeptide Y Receptor (∗)
Hope et al. Characterization of a human 5‐hydroxytryptamine3 receptor type A (h5‐HT3R‐AS) subunit stably expressed in HEK 293 cells
Shiraishi et al. Inhibition by Tramadol of Muscarinic Receptor-Induced Responses in Cultured Adrenal Medullary Cells and in Xenopus laevis Oocytes Expressing Cloned M1Receptors
WO1994014957A3 (en) Dna encoding 5-ht4 serotonin receptors and uses thereof
Thany et al. Identification and localization of the nicotinic acetylcholine receptor alpha3 mRNA in the brain of the honeybee, Apis mellifera
US20030077662A1 (en) Polynucleotides encoding SREB2 receptor
Emorine et al. The human β3-adrenergic receptor: relationship with atypical receptors
Mills et al. Autoradiographic mapping of [3H] sumatriptan binding in cat brain stem and spinal cord
WO2002033079A3 (en) Human g-protein coupled receptor and uses thereof
JPH07509601A (en) Cloning and expression of gonadotropin-releasing hormone receptors
Rønnekleiv et al. Downregulation of μ-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment
DE60031241T2 (en) KALIUM CHANNELS AND GENES CODING THESE KALIUM CHANNELS
Gulati et al. Brain and spinal cord 5-HT2 receptors of morphine-tolerant-dependent and-abstinent rats
Burke et al. Effect of postmortem factors on muscarinic receptor subtypes in rat brain
Manzanares et al. δ-Opioid receptor-mediated regulation of central dopaminergic neurons in the rat
Skattebøl et al. 6-Hydroxydopamine treatment increases β-adrenoceptors and Ca2+ channels in rat heart
EP1241259A1 (en) Peptide having pronociceptive properties
Reader et al. Selective noradrenergic denervation and 3H-prazosin binding sites in rat neocortex
EP0542920A1 (en) Cannabinoid receptor
WO2002028897A3 (en) Human g-protein coupled receptor and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001980469

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002536447

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001980469

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001980469

Country of ref document: EP